CALGARY, July 23, 2014 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization. Her accomplished employment record includes past notable positions such as CEO of Pathway Therapeutics Inc., President of Phenomix Corporation, Vice President, Preclinical Research and Exploratory Development SUGEN/Pharmacia/Pfizer, and Director, Virology at Gilead Sciences. Notably, Julie was a key contributor to the successful development of multiple FDA approved products including anti-virals (Vistide™, Viread™, Hepsera™) and anti-cancer agents (SUTENT™, Palladia™).
Dr. Cherrington remarked, "I am very excited to be joining Zenith Epigenetics at such an important time in the growth of the company. We are set to embark on the first clinical application of the strong scientific foundation of Zenith".
Donald J. McCaffrey, founding CEO, will assume the title of Chairman and Dr. Peter Johann will act as Lead Director. "I am very proud of the progress made by Zenith in the past year and am delighted to hand over the reins to Julie to lead the company, advancing our programs and creating value for Zenith. I look forward to working with Julie and to continue supporting the company in my role as Chairman of the Board of Directors", commented Don McCaffrey.
Zenith Epigenetics Corp. is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics by applying its proprietary epigenetics platform. Zenith's bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well.
SOURCE Zenith Epigenetics Corp.